Poolbeg Pharma says Gilead in favour of its combination with Hookipa.
Poolbeg Pharma updated the market on its potential combination with Hookipa Pharma on Friday, clarifying Gilead Sciences’ role in the proposed concurrent fundraise.
Poolbeg Pharma
10 January 2025 16:06:15
Source: Sharecast
The AIM-traded firm said Gilead, which holds existing contractual obligations with Hookipa, had expressed its intention to participate in the fundraise with a contribution of up to $8.7495m.
Additionally, Gilead indicated it would align its vote with the Hookipa board's recommendation if a formal offer was made.
Discussions regarding the potential merger remained non-binding and non-exclusive.
Poolbeg warned that there was no certainty that a firm offer would materialise, or that a transaction would be completed.
At 1545 GMT, shares in Poolbeg Pharma were down 7.14% at 5.2p.
Reporting by Josh White for Sharecast.com.
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
